The Latest Cardiac and Vascular News
~ Strategic transaction to meaningfully reduce interest expense ~ ~ Immediately earnings accretive in 2023 ~ PLANO, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (the “Company”), a leading medical device outsource manufacturer, announces the closing of its offering of $500 million aggregate principal amount of […]
Granted Korean Patent for its MyoVista® Wavelet Technology Southlake, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool […]
Significantly Refreshed Board Overseeing Successful Execution of Amarin’s Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa’s Slate in Every Critical Area Chairman Per Wold-Olsen Brings Critical Experience and Leadership Releases Additional Board Videos Available at www.voteamarin.com Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card DUBLIN, […]
CLEARWATER, Fla., Feb. 1, 2023 /PRNewswire/ — The team at the Center for Advanced Valve and Structural Heart Care at BayCare’s Morton Plant Hospital achieved another first when they used the minimally invasive Transcatheter Aortic Valve Replacement (TAVR) procedure to treat a patient suffering from aortic regurgitation. The team led by Joshua Rovin, […]
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively Company raises […]
McDermott + Bull Partner Ken Dropiewski talks with Gilde Healthcare General Partner Geoff Pardo about what his team looks for in prospective partners in new venture opportunities.
• First randomized controlled clinical trial to evaluate VX1-guided ablation compared to conventional anatomical ablation approaches to treat persistent atrial fibrillation • International, multi-center trial involving 26 sites, 374 patients is expected to report results in 2024 MARSEILLE, France, Feb. 02, 2023 (GLOBE NEWSWIRE) — Volta Medical, a pioneering health technology […]
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on February 1, 2023 that were approved by the Compensation Committee of its Board of […]
Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S. There are currently no FDA approved treatments for PH-HFpEF CHAPEL HILL, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused […]
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to […]
